5JE Stock Chart & Stats
€1.62
-€0.03(-0.91%)
At close: 4:00 PM EST
€1.62
-€0.03(-0.91%)
Day’s Range― - ―
52-Week Range€1.23 - €3.31
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€48.34M
Enterprise Value€667.26
Total Cash (Recent Filing)€43.52M
Total Debt (Recent Filing)€157.09M
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Oct 22, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding31,043,884
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)€19.13M
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationPositive TTM operating and free cash flow indicates the business is currently converting operations into cash, improving financial resilience and providing funding capacity even though the earnings base remains under pressure.
Improved Operating Cost StructureA solid EBITDA margin suggests operating costs have improved from the heavy losses seen in 2022–2023. Sustaining this structure could support eventual profitability if revenue growth and gross margins recover.
Scalable Licensing ModelThe licensing model can extend BIP across partners’ medical-device platforms without requiring Bactiguard to manufacture every unit. Broader adoption could create recurring, volume-linked revenue and expand market reach.
Bears Say
Persistent Net LossesOngoing net losses and negative EBIT show that the improved EBITDA profile has not yet translated into sustainable bottom-line earnings. This limits internal capital formation and leaves profitability dependent on further operational improvement.
Gross Margin CompressionThe sharp reduction in gross margin weakens earnings resilience and raises concerns about product mix, pricing power, or cost structure. Unless reversed, it can constrain operating leverage and delay the path to consistent profitability.
Dependence On Partner AdoptionPartner-based licensing expands reach but makes revenue dependent on external manufacturers’ adoption, commercialization, and unit volumes. Delays or weak uptake across partner products could restrict the pace and predictability of durable growth.
Bactiguard Holding AB News
5JE FAQ
What was Bactiguard Holding AB’s price range in the past 12 months?
Bactiguard Holding AB lowest stock price was €1.23 and its highest was €3.31 in the past 12 months.
What is Bactiguard Holding AB’s market cap?
Bactiguard Holding AB’s market cap is €48.34M.
When is Bactiguard Holding AB’s upcoming earnings report date?
Bactiguard Holding AB’s upcoming earnings report date is Oct 22, 2026 which is in 63 days.
How were Bactiguard Holding AB’s earnings last quarter?
Bactiguard Holding AB released its earnings results on Jul 14, 2026. The company reported -€0.018 earnings per share for the quarter, beating the consensus estimate of -€0.027 by €0.009.
Is Bactiguard Holding AB overvalued?
According to Wall Street analysts Bactiguard Holding AB’s price is currently Overvalued.
Does Bactiguard Holding AB pay dividends?
Bactiguard Holding AB does not currently pay dividends.
What is Bactiguard Holding AB’s EPS estimate?
Bactiguard Holding AB’s EPS estimate is -0.02.
How many shares outstanding does Bactiguard Holding AB have?
Bactiguard Holding AB has 31,043,884 shares outstanding.
What happened to Bactiguard Holding AB’s price movement after its last earnings report?
Bactiguard Holding AB reported an EPS of -€0.018 in its last earnings report, beating expectations of -€0.027. Following the earnings report the stock price went down -1.521%.
Which hedge fund is a major shareholder of Bactiguard Holding AB?
Currently, no hedge funds are holding shares in DE:5JE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bactiguard Holding AB
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.